Affinage

CD300A

CMRF35-like molecule 8 · UniProt Q9UGN4

Length
299 aa
Mass
33.2 kDa
Annotated
2026-04-28
71 papers in source corpus 30 papers cited in narrative 29 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CD300A is an ITIM-bearing inhibitory immunoreceptor expressed broadly on myeloid and lymphoid cells that recognizes phosphatidylserine (PS) and phosphatidylethanolamine (PE) exposed on apoptotic cells, activated cells, extracellular vesicles, and enveloped virus particles through a cavity in its IgV-like extracellular domain (PMID:22185693, PMID:22302738, PMID:26468529). Upon ligand engagement, its cytoplasmic ITIMs are phosphorylated (requiring Lck in T cells) and recruit SHP-1 as the principal effector phosphatase—or SHIP-1 in the context of Kit signaling—to suppress diverse activating pathways including FcεRI, BCR, FcγRIIa, Kit, TLR4/MyD88, TLR9/MyD88, and CD300b-DAP12, thereby dampening degranulation, cytokine production, calcium flux, proliferation, and transmigration across multiple immune cell types (PMID:10540326, PMID:22537350, PMID:18424727, PMID:22043923, PMID:34652960). CD300A also promotes neutrophil apoptosis via caspase-8, negatively regulates efferocytosis by opposing CD300b-DAP12 activating signals on myeloid cells, and serves as an attachment factor for dengue virus through PE/PS binding that facilitates clathrin-mediated endocytic entry (PMID:34002852, PMID:34652960, PMID:26468529). In vivo, CD300A deficiency exacerbates anaphylaxis, alters allergic airway inflammation, enhances efferocytosis after ischemic stroke, and modifies tumor immune evasion through regulation of dendritic cell–T cell crosstalk (PMID:40073110, PMID:25911756, PMID:34652960, PMID:34751648).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1999 High

    Establishing CD300a as an inhibitory receptor resolved whether this orphan Ig-superfamily molecule functioned as an activating or inhibitory regulator of NK cytotoxicity, showing it recruits SHP-1 and SHP-2 upon ITIM phosphorylation to suppress killing.

    Evidence Cross-linking and co-immunoprecipitation after pervanadate treatment in human NK cells

    PMID:10540326

    Open questions at the time
    • Physiological ligand unknown
    • Relative contribution of SHP-1 vs SHP-2 not determined
    • Receptor structure not yet characterized
  2. 2000 High

    Gene structure characterization defined CD300a as a single IgV-domain type I transmembrane protein with three ITIMs, establishing the molecular framework for subsequent signaling studies.

    Evidence Genomic clone isolation, exon-intron mapping, chromosomal localization to 17q25

    PMID:10746781

    Open questions at the time
    • No crystal structure
    • ITIM functional hierarchy not tested
  3. 2005 High

    Extension beyond NK cells demonstrated CD300a inhibits FcεRI/Kit-driven mast cell degranulation and IL-5/eotaxin/GM-CSF signaling in eosinophils, establishing it as a broadly acting inhibitory receptor on innate effector cells; SHP-1 but not SHP-2 was required in eosinophils.

    Evidence Cross-linking assays, calcium flux, degranulation, and signaling Western blots in human mast cells and eosinophils; murine allergic peritonitis model

    PMID:16254138 PMID:16339535

    Open questions at the time
    • Ligand still unidentified
    • In vivo role in allergy only partially addressed
  4. 2006 High

    Bispecific antibody co-aggregation strategy proved CD300a can be therapeutically redirected to inhibit FcεRI and CCR3 signaling, reversing airway inflammation in vivo, while SAXS revealed the extracellular domain is a monomeric Ig-fold.

    Evidence Bispecific antibody constructs with degranulation/calcium readouts; murine passive cutaneous anaphylaxis and airway inflammation models; SAXS structural analysis

    PMID:16750992 PMID:16949664 PMID:17088133

    Open questions at the time
    • No atomic-resolution structure
    • Natural ligand unknown
    • Mechanism of co-ligation selectivity unclear
  5. 2007 Medium

    Discovery that LPS and GM-CSF rapidly upregulate CD300a surface expression from intracellular stores on neutrophils, and that CD300a selectively inhibits FcγRIIa but not TLR4-mediated ROS, revealed stimulus-dependent receptor mobilization and pathway-selective inhibition.

    Evidence Flow cytometry and co-ligation assays in neutrophils and HL-60 cells

    PMID:17588661

    Open questions at the time
    • Intracellular pool identity not characterized
    • Mechanism of TLR4-ROS resistance to inhibition not explained
  6. 2008 High

    Identification that Kit-driven CD300a phosphorylation recruits SHIP-1 (not SHP-1) established that the phosphatase recruited depends on the activating receptor context, adding nuance to the inhibitory signaling model; separately, CD300a modulated TLR7/9 responses in plasmacytoid DCs with IFN-α feedback.

    Evidence Co-IP in mast cells with bispecific Kit-CD300a antibody; cytokine measurement in pDCs with cross-linking antibodies

    PMID:18424727 PMID:18535206

    Open questions at the time
    • Structural basis for differential phosphatase recruitment unknown
    • pDC study did not distinguish CD300a from CD300c
  7. 2011 High

    Two breakthroughs identified PS as the natural ligand of CD300a and demonstrated CD300a inhibits BCR signaling in B cells, unifying the receptor's function as a sensor of aminophospholipid exposure across lymphoid and myeloid compartments.

    Evidence CD300a-Fc binding to apoptotic cells with SHP-1 co-IP; BCR co-ligation and siRNA knockdown in B cell lines

    PMID:21482706 PMID:22185693

    Open questions at the time
    • PE binding not yet recognized
    • Binding site residues not mapped
    • No KO mouse data yet
  8. 2012 High

    A cluster of studies defined the molecular mechanism: PE and PS bind within a cavity in the IgV domain (mutagenesis-mapped), Lck phosphorylates the ITIMs, SHP-1 is the required effector phosphatase, and CD300a-PS interaction on apoptotic cells suppresses mast cell inflammatory cytokines in vivo during sepsis; CD300a also selectively blocks TLR4/9-MyD88 but not TLR3-TRIF signaling.

    Evidence SPR/mutagenesis for lipid binding; chimeric receptors in Jurkat/DT40 for ITIM-phosphatase dissection; CD300a KO mice in CLP sepsis model; TLR pathway dissection with NF-κB reporters and ITIM peptides

    PMID:22043923 PMID:22302738 PMID:22537350 PMID:22826299

    Open questions at the time
    • No crystal structure of lipid-bound complex
    • In vivo role of individual ITIMs not tested
    • Relative contribution of PS vs PE in physiological settings unclear
  9. 2013 High

    Residue-level discrimination between CD300A (F56-L57) and CD300C (L63-R64) for PE binding was mapped, and CD300A was shown to dominate over the activating CD300C when co-expressed, explaining how inhibitory signaling prevails; blocking CD300a-PS enhanced NK killing of tumors, implicating PS-mediated immune evasion.

    Evidence Chimeric reporter cell lines with residue swaps; NK cytotoxicity with CD300a-blocking antibodies

    PMID:23372157 PMID:23640773

    Open questions at the time
    • Unknown additional ligand(s) on tumor cells
    • In vivo tumor immune evasion via CD300a not yet shown
  10. 2015 High

    CD300a was identified as a viral entry factor: it binds PE/PS on dengue virus envelopes to enhance clathrin-mediated endocytic entry (mutagenesis confirmed); in allergic disease, CD300a on DCs sensing alum-induced apoptotic cells promotes Th2 skewing; and herpesvirus US3 kinase exploits CD300a ligand exposure to evade NK killing.

    Evidence CD300a-Ig DENV binding with mutagenesis and clathrin inhibitors; CD300a KO mice in airway allergy model; pseudorabies virus infection with PAK inhibitors and NK lysis assays

    PMID:25911756 PMID:26468529 PMID:26581992

    Open questions at the time
    • Breadth of enveloped viruses exploiting CD300a not systematically assessed
    • Molecular mechanism of Th2 skewing by CD300a-PS on DCs not fully resolved
  11. 2021 High

    Multiple in vivo studies revealed CD300a as a central checkpoint: it opposes CD300b-DAP12-driven efferocytosis after stroke (KO or antibody blockade improves outcome), induces neutrophil apoptosis via caspase-8 to resolve gouty inflammation, modulates neutrophil phagocytosis during UTI, and suppresses DC TLR3-TRIF-IFN-β signaling triggered by tumor-derived EVs to promote Treg accumulation and tumor growth.

    Evidence CD300a KO mice in MCAO stroke, MSU gout, UPEC UTI, and B16 melanoma models; agonistic antibody caspase-8 cleavage assays; endosomal fractionation of DC-TEV pathway

    PMID:34002852 PMID:34268737 PMID:34652960 PMID:34751648

    Open questions at the time
    • CD300a-CD300b signaling crosstalk mechanism at molecular level not defined
    • Caspase-8 activation pathway downstream of CD300a not fully characterized
    • Therapeutic window for anti-CD300a antibody in stroke or cancer not established
  12. 2023 Medium

    The PPARβ/δ→CD300a→SHP-1⊣Syk signaling axis was validated pharmacologically in mast cells after germinal matrix hemorrhage, confirming transcriptional regulation of CD300a feeds into its canonical inhibitory signaling cascade.

    Evidence PPARβ/δ agonist GW0742 treatment and CD300a/PPARβ/δ siRNA in a rat GMH model with Western blotting

    PMID:37995951

    Open questions at the time
    • Direct PPARβ/δ binding to CD300a promoter not shown in this study
    • Rat model; human translational data lacking
  13. 2025 High

    Epistasis experiments with CD300a/CD300lf double-KO mice demonstrated cooperative inhibition of mast cell activation, with both receptors co-localizing at PS-enriched poles on activated mast cells; CD300lf additionally recognizes ceramide, providing a stronger inhibitory signal than PS alone.

    Evidence Single and double KO bone marrow-derived mast cells; imaging co-localization; passive systemic anaphylaxis with graded phenotypes

    PMID:40073110

    Open questions at the time
    • Structural basis of polar co-localization not defined
    • Whether ceramide also engages CD300a directly is untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Despite extensive functional characterization, an atomic-resolution crystal or cryo-EM structure of CD300a bound to PS or PE remains unavailable, the hierarchy and individual contributions of the three ITIMs in physiological signaling are not genetically resolved in vivo, and whether CD300a serves as a viable therapeutic target in cancer immune evasion or neuroinflammation lacks clinical data.
  • No atomic structure of lipid-bound CD300a
  • Individual ITIM contributions not resolved by knock-in mutations in vivo
  • No clinical trial data for CD300a-targeted therapy

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 6 GO:0008289 lipid binding 4
Localization
GO:0005886 plasma membrane 5 GO:0005768 endosome 1
Pathway
R-HSA-168256 Immune System 9 R-HSA-162582 Signal Transduction 5 R-HSA-1643685 Disease 3
Partners
CD300BCD300CCD300LFINPP5DLCKPTPN11PTPN6

Evidence

Reading pass · 29 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 CD300a (IRp60) is an inhibitory receptor on NK cells that, upon tyrosine phosphorylation (induced by sodium pervanadate), associates with the SH2-containing phosphatases SHP-1 and SHP-2, thereby inhibiting NK cell cytotoxicity. Monoclonal antibody generation, cross-linking assays, co-immunoprecipitation after pervanadate treatment European journal of immunology High 10540326
2000 CD300a (CMRF-35H) gene is located on human chromosome 17, encodes a single V-type Ig-like domain extracellular protein with three ITIMs in its cytoplasmic tail, and spans ~12 kb with seven exons. Genomic clone isolation, intron-exon organization mapping, chromosomal mapping Tissue antigens High 10746781
2005 CD300a (IRp60) cross-linking on human mast cells inhibits IgE-induced degranulation and SCF-mediated survival via tyrosine phosphorylation, phosphatase recruitment (SHP-1/SHP-2), and termination of cellular calcium influx. Cross-linking with monoclonal antibodies, flow cytometry (Ca2+ flux), tryptase/IL-4 release assays, murine allergic peritonitis model with CD300a neutralization Journal of immunology High 16339535
2005 CD300a (IRp60) cross-linking on human eosinophils inhibits IL-5-mediated JAK2 phosphorylation and eotaxin/IL-5/GM-CSF-mediated ERK1/2 and p38 phosphorylation; CD300a undergoes tyrosine phosphorylation and recruits SHP-1 but not SHP-2 in eosinophils. Cross-linking assays, Western blotting for phosphorylation, transmigration assays, cytokine/apoptosis assays Blood High 16254138
2006 CD300a co-aggregation with IgE receptor (via bispecific antibody) inhibits IgE-mediated mast cell degranulation by inhibiting FcεRI signaling events including calcium influx; linkage of CD300a to CCR3 similarly inhibits eosinophil and mast cell activation and reverses airway inflammation in a chronic asthma model. Bispecific antibody fragment generation, phosphorylation/calcium flux FACS, degranulation assays, murine passive cutaneous anaphylaxis and airway inflammation models Journal of allergy and clinical immunology High 16750992 17088133
2006 CD300a extracellular domain adopts a monomeric immunoglobulin-like fold in solution, as determined by SAXS and homology modeling. Recombinant protein expression/refolding from E. coli, small-angle X-ray scattering (SAXS), homology modeling International journal of biological macromolecules Medium 16949664
2007 CD300a surface expression on human neutrophils is rapidly increased by LPS and GM-CSF via translocation of an intracellular pool to the cell surface; co-ligation of CD300a with FcγRIIa (CD32a) inhibits FcγRIIa-mediated signaling selectively without inhibiting TLR4-mediated ROS production. Flow cytometry, HL-60 differentiation model, co-ligation assays Molecular immunology Medium 17588661
2008 CD300a co-aggregation with Kit (CD117) via bispecific antibody inhibits SCF-induced signaling in mast cells, which is mediated by Kit-driven tyrosine phosphorylation of CD300a and recruitment of SHIP-1 (but not SHP-1); this impairs mast cell differentiation, survival, and activation. Bispecific antibody library, co-immunoprecipitation, Western blotting, in vitro differentiation/survival assays, murine cutaneous anaphylaxis model Journal of immunology High 18424727
2008 CD300a/c triggering on plasmacytoid dendritic cells reduces TNF-α and increases IFN-α secretion in response to TLR7/9 ligands; IFN-α feeds back to down-regulate CD300a/c expression. Cross-linking antibody stimulation, cytokine ELISA, neutralizing antibody experiments Blood Medium 18535206
2011 CD300a extracellular domain (as Fc fusion protein) specifically binds phosphatidylserine (PS) exposed on apoptotic cells; PS binding induces SHP-1 recruitment by CD300a in mast cells in response to LPS. CD300a-Fc fusion protein, binding assay to apoptotic cells, SHP-1 co-immunoprecipitation Biochemical and biophysical research communications High 22185693
2011 CD300a co-ligation with BCR on B cells inhibits Ca2+ mobilization and NFAT transcriptional activity; siRNA knockdown of CD300a increases BCR-mediated proliferation, confirming its inhibitory capacity. Co-ligation assays, calcium mobilization FACS, NFAT reporter assay, siRNA knockdown, proliferation assays Blood High 21482706
2012 CD300a binds phosphatidylethanolamine (PE) and phosphatidylserine (PS) on dead cells; mutational studies identified residues forming a cavity in the IgV domain where PE/PS hydrophilic heads penetrate; CD300a down-regulates macrophage phagocytosis of apoptotic cells and its ectopic expression in CD300a-negative lines decreases engulfment. Surface plasmon resonance, ultracentrifugation, ELISA, reporter cell assays, site-directed mutagenesis, structural modeling, phagocytosis assays Blood High 22302738
2012 CD300a is a non-phagocytic PS receptor on mast cells that delivers an inhibitory signal suppressing LPS-induced inflammatory cytokine and chemokine production; after apoptotic cell accumulation in vivo (cecal ligation and puncture), CD300a-PS interaction suppresses neutrophil chemoattractant release from mast cells. CD300a-deficient mice, peritoneal mast cell isolation, cytokine/chemokine measurement, CLP model, antibody blockade of CD300a-PS interaction Journal of experimental medicine High 22826299
2012 CD300a ITIM tyrosine phosphorylation requires the src kinase Lck; phosphorylated ITIMs dock both SHP-1 and SHP-2, but only SHP-1 is required for CD300a inhibitory activity, as shown by siRNA knockdown and phosphatase-deficient DT40 cell lines. KIR-CD300a chimeric receptor in Jurkat T cells, siRNA knockdown of SHP-1/SHP-2/SHIP, DT40 phosphatase-deficient cell lines, calcium mobilization and proliferation assays BMC immunology High 22537350
2012 CD300a selectively blocks TLR4/MyD88 and TLR9/MyD88-mediated pro-inflammatory signaling through SHP-1 activation, but does not block TLR3/TRIF-mediated signaling (unlike CD300f which requires combined SHP-1 and SHP-2); ITIM peptides of CD300a mimic this selective inhibition. THP-1/U937 stimulation with TLR ligands, luciferase NF-κB reporter assay, Western blotting, synthetic ITIM peptides, signaling inhibitors Immunology High 22043923
2013 CD300a and CD300c both bind PS and additional unknown ligand(s) on tumor cells; blocking PS-CD300a interaction increases NK cell killing of tumor cells, demonstrating a tumor immune evasion mechanism. Anti-CD300a monoclonal antibody generation, NK cell cytotoxicity assays, antibody blocking experiments European journal of immunology Medium 23640773
2013 CD300C delivers FcRγ-dependent activating signals in mast cells and monocytes; CD300A and CD300C differ in ligand recognition at residues F56-L57 (CD300A) vs. L63-R64 (CD300C), with PE binding more strongly to CD300A; CD300A expression is dominant over CD300C in PE recognition/signaling when co-expressed. Epitope-discriminating antibodies, reporter cell lines expressing CD300A/C-CD3ζ chimeras, GFP reporter assay, cytokine production assays, co-expression experiments Journal of biological chemistry High 23372157
2013 CD300a mRNA and protein are upregulated following monocyte transendothelial migration; CD300a engagement reduces monocyte transmigration, siRNA knockdown increases transmigration rate, and activated CD300a causes F-actin cytoskeleton alterations and co-localizes with actin filaments. Transcriptional profiling, siRNA knockdown, anti-CD300a antibody treatment, migration assays, co-sedimentation with actin, immunofluorescence PloS one Medium 24058511
2014 PPARβ/δ directly regulates CD300a transcription in macrophages; CD300a-deficient mice on high-fat diet develop chronic intestinal inflammation with prolonged IL-6 secretion from macrophages in response to LPS/TLR4-MyD88 signaling. CD300a KO mice, high-fat diet model, bone marrow transplantation, LPS stimulation, cytokine measurement Scientific reports Medium 24958459
2015 CD300a binds DENV particles directly via PE (predominantly) and PS on the viral envelope, acting as an attachment factor that enhances DENV internalization through clathrin-mediated endocytosis; mutation of IgV domain residues critical for phospholipid binding abrogates CD300a-mediated viral enhancement. CD300a-Ig fusion binding to DENV, clathrin inhibitor experiments, site-directed mutagenesis of phospholipid-binding residues, viral infection assays, antibody inhibition in primary macrophages Journal of virology High 26468529
2015 CD300a on inflammatory dendritic cells binds PS on apoptotic cells generated by alum adjuvant, promoting Th2 immune responses; CD300a-deficient mice show reduced eosinophilia, IgE, and airway hyperreactivity after alum+OVA immunization, and their DCs induce less IL-4 from CD4+ T cells. CD300a KO mice, allergic airway inflammation model, DC purification and co-culture, neutralizing antibody blockade Journal of immunology High 25911756
2015 Pseudorabies virus US3 kinase triggers increased CD300a binding to the surface of infected cells via aminophospholipid ligands and group I p21-activated kinases (PAKs), thereby protecting virus-infected cells from NK cell-mediated lysis. Virus infection assays, NK cell cytotoxicity assays, PAK inhibitors, aminophospholipid manipulation Journal of virology Medium 26581992
2021 CD300a on brain myeloid cells inhibits efferocytosis of apoptotic cells by blocking CD300b-DAP12 signaling; CD300a deficiency enhances efferocytosis, reduces DAMP release, and attenuates neurological deficit after ischemic stroke; anti-CD300a neutralizing antibody ameliorates stroke outcome. CD300a KO mice, MCAO model, efferocytosis assays, DAMP measurement, neutralizing antibody treatment, neurological scoring Science immunology High 34652960
2021 CD300a on dendritic cells inhibits tumor-derived extracellular vesicle (TEV)-mediated TLR3-TRIF signaling for IFN-β production; TEV co-culture with DCs induces CD300a internalization and incorporation of EVs into endosomes where CD300a suppresses TLR3-TRIF-IFN-β-Treg axis, resulting in Treg accumulation and tumor growth. CD300a KO mice, B16 melanoma transplantation, EV pharmacological inhibition, DC-TEV co-culture, endosomal fractionation, tumor-infiltrating Treg cell counting eLife High 34751648
2021 CD300a deficiency impairs neutrophil phagocytic ability during urinary tract infection despite increased accumulation at the infection site; UPEC's α-hemolysin toxin induces upregulation of CD300a ligands on infected bladder epithelial cells. CD300a KO mice, UPEC infection model, phagocytosis assays, bacterial burden measurement, α-hemolysin stimulation European journal of immunology Medium 34268737
2021 CD300a agonistic antibody induces apoptosis of human neutrophils via caspase-8 cleavage, contributing to resolution of MSU crystal-induced articular inflammation; CD300a KO mice show persistent neutrophil influx and reduced efferocytosis after MSU injection. CD300a KO mice, MSU crystal gout model, agonistic antibody treatment, caspase-8 cleavage assay, efferocytosis quantification Immunology Medium 34002852
2023 PPARβ/δ agonist GW0742 increases CD300a expression and SHP-1 phosphorylation in mast cells, reducing Syk phosphorylation and mast cell degranulation after germinal matrix hemorrhage; CD300a siRNA abolishes the protective effects. GMH rat model, siRNA knockdown of PPARβ/δ and CD300a, Western blotting for SHP-1 and Syk phosphorylation, mast cell degranulation markers Experimental neurology Medium 37995951
2025 CD300a and CD300lf cooperate to inhibit mast cell activation; both receptors co-localize with PS externalized on the outer leaflet upon activation with polar formation; CD300lf additionally binds extracellular ceramide, providing stronger inhibition than PS binding alone; double KO mice show more severe anaphylaxis than single KOs. KO mouse bone marrow-derived mast cells (single and double KO), imaging and flow cytometry for receptor localization, passive systemic anaphylaxis model with temperature readout Journal of immunology High 40073110
2024 CD300a specifically modulates PE-mediated phagocytic uptake by macrophages; CD300a and CD300b engage PE on apoptotic cells and extracellular vesicles through ITAM-containing adaptors and Syk kinase; CD300a expression curtails inflammatory responses of macrophages to PE particles containing LPS. Phagocytosis assays with PE-coated particles, CD300 family receptor knockdown/expression, Syk inhibitor experiments, LPS inflammatory response measurement bioRxivpreprint Medium bio_10.1101_2024.11.18.624161

Source papers

Stage 0 corpus · 71 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 152 22302738
1999 Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. European journal of immunology 137 10540326
2005 The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. Journal of immunology (Baltimore, Md. : 1950) 127 16339535
2005 The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 108 16254138
2015 The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection. Journal of virology 84 26468529
2015 The Biology and Disease Relevance of CD300a, an Inhibitory Receptor for Phosphatidylserine and Phosphatidylethanolamine. Journal of immunology (Baltimore, Md. : 1950) 78 25980030
2006 Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. The Journal of allergy and clinical immunology 77 16750992
2012 Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. The Journal of experimental medicine 75 22826299
2006 Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. The Journal of allergy and clinical immunology 74 17088133
2011 Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor. Biochemical and biophysical research communications 69 22185693
2008 CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 65 18535206
2007 The CD300a (IRp60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Molecular immunology 65 17588661
2011 CD300a is expressed on human basophils and seems to inhibit IgE/FcεRI-dependent anaphylactic degranulation. Cytometry. Part B, Clinical cytometry 57 22173928
2008 Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. Journal of immunology (Baltimore, Md. : 1950) 51 18424727
2011 CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection. Blood 50 21482706
2013 The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. European journal of immunology 49 23640773
2012 CD300a and CD300f differentially regulate the MyD88 and TRIF-mediated TLR signalling pathways through activation of SHP-1 and/or SHP-2 in human monocytic cell lines. Immunology 45 22043923
2021 CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. Science immunology 41 34652960
2011 Peripheral CD300a+CD8+ T lymphocytes with a distinct cytotoxic molecular signature increase in pregnant women with chronic chorioamnionitis. American journal of reproductive immunology (New York, N.Y. : 1989) 41 22077960
2000 The CMRF-35H gene structure predicts for an independently expressed member of an ITIM/ITAM pair of molecules localized to human chromosome 17. Tissue antigens 38 10746781
2010 Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin. PloS one 35 20498708
2016 Effect of CMV and Aging on the Differential Expression of CD300a, CD161, T-bet, and Eomes on NK Cell Subsets. Frontiers in immunology 34 27872625
2013 Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition. The Journal of biological chemistry 33 23372157
2015 Involvement of CD300a Phosphatidylserine Immunoreceptor in Aluminum Salt Adjuvant-Induced Th2 Responses. Journal of immunology (Baltimore, Md. : 1950) 30 25911756
2021 Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. eLife 29 34751648
2014 PPARβ/δ activation of CD300a controls intestinal immunity. Scientific reports 28 24958459
2018 Leukocyte CD300a Contributes to the Resolution of Murine Allergic Inflammation. Journal of immunology (Baltimore, Md. : 1950) 26 30315138
2013 The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosinophils. Allergy 23 23346884
2016 CD300c is uniquely expressed on CD56 bright Natural Killer Cells and differs from CD300a upon ligand recognition. Scientific reports 22 27040328
2007 Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression. Journal of leukocyte biology 22 17702825
2013 Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages. Innate immunity 21 24131792
2012 Expressions and inhibitory functions of CD300a receptors on purified human basophils. Experimental dermatology 21 23163658
2015 Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a. Journal of virology 20 26581992
2021 CD300a and CD300f molecules regulate the function of leukocytes. International immunopharmacology 19 33548578
2017 Differential Effect of Cytomegalovirus Infection with Age on the Expression of CD57, CD300a, and CD161 on T-Cell Subpopulations. Frontiers in immunology 19 28626460
2012 Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a. BMC immunology 19 22537350
2011 Differential expression of CD300a/c on human TH1 and TH17 cells. BMC immunology 19 22046970
2015 Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget 17 26435477
2022 CD300a Receptor Blocking Enhances Early Clearance of Leishmania donovani From Its Mammalian Host Through Modulation of Effector Functions of Phagocytic and Antigen Experienced T Cells. Frontiers in immunology 15 35116028
2018 CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. Oncotarget 15 29938007
2019 The immunoreceptor CD300a controls the intensity of inflammation and dysfunction in a model of Ag-induced arthritis in mice. Journal of leukocyte biology 13 31107994
2006 Molecular analysis and solution structure from small-angle X-ray scattering of the human natural killer inhibitory receptor IRp60 (CD300a). International journal of biological macromolecules 13 16949664
2018 Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/β-catenin pathway. OncoTargets and therapy 11 30573974
2017 IrC2/Bf - A yeast and Borrelia responsive component of the complement system from the hard tick Ixodes ricinus. Developmental and comparative immunology 10 29061482
2018 Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers. Frontiers in immunology 9 30083165
2025 Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism. Blood advances 8 39368806
2021 Impact of Cytomegalovirus and Age on T-Cell Subsets Defined by CD161, CD300a, and/or CD57 Expression in Healthy Andalusians. The journals of gerontology. Series A, Biological sciences and medical sciences 8 33993242
2021 CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis. Immunology 8 34002852
2021 The inhibitory receptor CD300a is essential for neutrophil-mediated clearance of urinary tract infection in mice. European journal of immunology 8 34268737
2023 Leishmania donovani induces CD300a expression to dampen effector properties of CD11c+ dendritic and antigen activated CD8+ T cells. Acta tropica 7 36610528
2021 Optimizing Bioremediation: Elucidating Copper Accumulation Mechanisms of Acinetobacter sp. IrC2 Isolated From an Industrial Waste Treatment Center. Frontiers in microbiology 7 34795645
2020 Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a. Scientific reports 7 32269232
2013 Transcriptional profiling of human monocytes identifies the inhibitory receptor CD300a as regulator of transendothelial migration. PloS one 7 24058511
2024 Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 5 38425216
2023 CD300a Regulates Mouse Macrophage Functionality in Allergic Inflammation. International archives of allergy and immunology 5 36928079
2015 Chicken CD300a homolog is found on B lymphocytes, various leukocytes populations and binds to phospholipids. Developmental and comparative immunology 5 25681077
2020 CD300a identifies a CD4+ memory T cell subset with a higher susceptibility to HIV-1 infection. AIDS (London, England) 4 32287074
2025 CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity. Cancers 3 40507267
2023 Development of Monoclonal Antibodies Specific to Either CD300AR111 or CD300AQ111 or Both. Monoclonal antibodies in immunodiagnosis and immunotherapy 3 37902989
2025 Inhibitory immunoreceptors CD300a and CD300lf cooperate to regulate mast cell activation. Journal of immunology (Baltimore, Md. : 1950) 2 40073110
2023 Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites. Molecular immunology 2 37778149
2018 CD300A inhibits tumor cell growth by downregulating AKT phosphorylation in human glioblastoma multiforme. International journal of clinical and experimental pathology 2 31949725
2025 A Humanized Monoclonal Antibody Against CD300A Ameliorates Acute Ischemic Stroke in Humanized Mice. Monoclonal antibodies in immunodiagnosis and immunotherapy 1 39804190
2025 CD300A+ CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon-Alpha Therapy. Alimentary pharmacology & therapeutics 1 40454546
2024 The Role of TIM-1 and CD300a in Zika Virus Infection Investigated with Cell-Based Electrical Impedance. Biosensors 1 39194591
2023 GW0742 reduces mast cells degranulation and attenuates neurological impairments via PPARβ/δ/CD300a/SHP1 pathway after GMH in neonatal rats. Experimental neurology 1 37995951
2026 Efferocytosis-linked genetic signature predicts rheumatoid arthritis risk and highlights CD300A as a novel target. Immunology letters 0 41621689
2026 CD300a Immunoreceptor Blocking Attenuates Neuronal Apoptosis by Regulating Efferocytosis and Promotes Hindlimb Functional Recovery after Acute Spinal Cord Injury in Mice. Journal of neurotrauma 0 41700726
2026 CD300a as a Potential Immune Checkpoint in Breast Cancer: Insights from in vivo and in vitro Models. International archives of allergy and immunology 0 41871214
2025 Evolutionary analysis of CD300A and CD300C paired receptors in primates. Frontiers in immunology 0 40977689
2023 Human IgMhiCD300a+ B Cells Are Circulating Marginal Zone Memory B Cells That Respond to Pneumococcal Polysaccharides and Their Frequency Is Decreased in People Living with HIV. International journal of molecular sciences 0 37762055